Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063792 | 1.00 | SLC6A1 (0.60) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL5498837 | 1.00 | SLC6A1 (0.60) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6956415 | 0.99 | ALDH1A1 (0.60) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL8196337 | 0.99 | ALDH1A1 (0.60) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL8936308 | 0.91 | SLC6A1 (0.51) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL7605820 | 0.91 | SLC6A1 (0.52) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL7605253 | 0.91 | SLC6A1 (0.65) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL7609305 | 0.91 | SLC6A1 (0.65) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL7604278 | 0.91 | SLC6A1 (0.65) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL7609301 | 0.91 | SLC6A1 (0.65) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066570-A1 | Methods for treating sleep disorders | HYPNION, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066570-A1 | Methods for treating sleep disorders | HYPNION, INC. | 2007-03-22 | — | — | US | disclosed |
| WO-2004112705-A2 | METHODS FOR TREATING SLEEP DISORDERS | HYPNION, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-1140084-A1 | NOVEL FORMULATION | NOVO NORDISK A/S (DK) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037081-A1 | NOVEL FORMULATION | NOVO NORDISK A/S (DK) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066570-A1 | Methods for treating sleep disorders | HCRTR2, HNMT, HCRTR1 | SLC6A1 100/4885ALDH1A1 1567/4885LMNA 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.